Positive results from Phase 3 study of Medicago’s plant-based COVID-19 vaccine candidate announced

By | December 9, 2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.